Vision RT’s “fast, intuitive and powerful” new software platform
21 October 2019. Vision RT is proud to announce the 510(k) clearance, launch and first clinical use of its new Version 6 platform for AlignRT. This innovation transforms the user experience for SGRT and is already being hailed as a step forward in terms of speed, performance and usability. In some workflows, the number of operations has been reduced by over 60%, advancing efficiency and ease of adoption. In addition, the Version 6 platform supports Advanced Camera Optimization, a new technique which delivers non-coplanar tracking accuracy of ≤ 0.3mm / ≤ 0.2°, including the most challenging clinically realistic configurations; couch rotations, pod occlusions and deep isocenters.
Jacqui Dorney, Specialist Service Lead at GenesisCare UK, has been involved in the first clinical use of the new platform. “We have been using Version 6 of the AlignRT software for the last few days and have treated 25 patients and over 100 fractions so far. Initially, we were planning to trial this new release for a limited period before moving back to our tried and tested Version 5. However, we have found Version 6 to be so fast, intuitive and powerful that we have decided that we cannot give it up!”
Dr Adrian Barrett, Vice President of New Product Delivery at Vision RT, said “Vision RT now has a growing team of over 60 engineers innovating to continue our leadership within SGRT. Version 6 is a new platform for our market-leading AlignRT product, designed to deliver an even faster, and easier-to-use experience. We are extremely encouraged by the feedback we have had from users, and I want to thank the many radiation therapists, physicists and oncologists who gave input to this major innovation.”
About Vision RT
Vision RT defines the standard of care in Surface Guided Radiation Therapy. We provide superior solutions for the radiotherapy market, with products installed in many of the leading treatment centres in the world, including around 70% of the 50 US News “Best Hospitals for Cancer”. With 70 granted patents plus 51 pending, we continue to innovate in the radiation oncology space and are committed to making SGRT the standard of care for all patients, worldwide.
Vision RT is part of the William Demant Invest (WDI) family, a leading Danish Medtech investor with a long-term investment perspective. The companies in William Demant Invest employed on average 17,024 people during 2017 with a total revenue of $3bn.